Please login to the form below
CALD gene therapy
This page shows the latest CALD gene therapy news and features for those working in and with pharma, biotech and healthcare.
bluebird bio’s CALD gene therapy Skysona gains positive opinion from CHMP
bluebird bio’s cerebral adrenoleukodystrophy (CALD) gene therapy Skysona has moved closer towards EU approval after gaining a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for ... bluebird bio's Skysona is a
Latest news
-
bluebird bio reveals long-term data for Lenti-D gene therapy in CALD
bluebird bio has revealed new data from its clinical development programme for Lenti-D gene therapy in cerebral adrenoleukodystrophy (CALD). ... bluebird bio’s Lenti-D (eli-cel/elivaldogene autotemcel) is a potential one-off gene therapy designed to
-
EMA accepts application for bluebird bio’s Lenti-D in CALD
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for bluebird bio’s Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD). ... Bluebird bio's Lenti-D (eli-cel/elivaldogene autotemcel) is a potential
-
bluebird bio reveals further encouraging data for CALD gene therapy
Study shows continued benefit in treatment of rare disease. Last year, Bluebird Bio claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – it has now ... Lenti-D is Bluebird’s lead gene
-
bluebird bags breakthrough status for CALD gene therapy
News comes after impressive data from a phase II/III trial. Bluebird Bio has claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – a rare ... Bluebird’s gene therapy approach could do away
bluebird bio reveals long-term data for Lenti-D gene therapy in CALD
bluebird bags breakthrough status for CALD gene therapy
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Europe is the test ground for the gene therapy pioneer’s outcomes-based model, which could set the standard for the emerging sector. ... pipeline. This incudes Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), a rare,
Bluebird: on a mission to ‘recode’ the DNA of healthcare
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
-
Events Executive
-
Depending on Experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Sanofi to buy mRNA tech partner, Translate Bio, for $3.2bn
- Novartis to proceed with phase 3 trial for intrathecal OAV-101 in older SMA patients
- Ask the writers: Transitioning from academia to medical writing
- Amanda Pritchard becomes NHS England’s first female chief executive
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
- A market-adapted agile approach to launch excellence
- Communicating for change – creating effective medical communications
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
